(Z)-5-hydroxy-3-((6-(pyridin-4-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one

ID: ALA4576372

PubChem CID: 155551975

Max Phase: Preclinical

Molecular Formula: C19H12N4O2S

Molecular Weight: 360.40

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C1Nc2ccc(O)cc2/C1=C/c1c(-c2ccncc2)nc2sccn12

Standard InChI:  InChI=1S/C19H12N4O2S/c24-12-1-2-15-13(9-12)14(18(25)21-15)10-16-17(11-3-5-20-6-4-11)22-19-23(16)7-8-26-19/h1-10,24H,(H,21,25)/b14-10-

Standard InChI Key:  RLFVMSYTFNBJFM-UVTDQMKNSA-N

Molfile:  

 
     RDKit          2D

 26 30  0  0  0  0  0  0  0  0999 V2000
   13.0049   -6.3089    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   12.9426   -4.9727    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.4915   -5.6635    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.7414   -5.1923    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   13.7778   -6.0176    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.5738   -6.2380    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   15.0296   -5.5491    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.5151   -4.9029    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.7355   -4.1070    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.8505   -5.5134    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.2940   -6.2115    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.1183   -6.1755    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.5002   -5.4421    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   17.0516   -4.7437    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.2288   -4.7831    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.1564   -3.5181    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.9690   -2.9006    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   13.3379   -3.6395    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.5578   -2.3214    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.2881   -2.7042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.9826   -2.2634    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.9480   -1.4398    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.2132   -1.0591    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.5217   -1.5021    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.9562   -4.3719    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   15.6446   -0.9959    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  5  1  0
  4  2  1  0
  2  3  2  0
  3  1  1  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  4  1  0
  8  9  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 10  1  0
  7 10  1  0
  9 16  2  0
 16 20  1  0
 19 17  1  0
 17 18  1  0
 18 16  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 19  1  0
 18 25  2  0
 22 26  1  0
M  END

Alternative Forms

  1. Parent:

    ALA4576372

    ---

Associated Targets(Human)

Leukemia cell (223 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NSCLC (640 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CNS carcinoma cell (76 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Melanoma cell line (83 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Ovarian carcinoma cell (138 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Renal cancer cell line (72 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Prostatic carcinoma cell (85 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Breast carcinoma cell (217 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 360.40Molecular Weight (Monoisotopic): 360.0681AlogP: 3.66#Rotatable Bonds: 2
Polar Surface Area: 79.52Molecular Species: NEUTRALHBA: 6HBD: 2
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 8.68CX Basic pKa: 3.92CX LogP: 2.52CX LogD: 2.49
Aromatic Rings: 4Heavy Atoms: 26QED Weighted: 0.42Np Likeness Score: -1.12

References

1. Morigi R, Locatelli A, Leoni A, Rambaldi M, Bortolozzi R, Mattiuzzo E, Ronca R, Maccarinelli F, Hamel E, Bai R, Brancale A, Viola G..  (2019)  Synthesis, in vitro and in vivo biological evaluation of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones as new potent anticancer agents.,  166  [PMID:30784885] [10.1016/j.ejmech.2019.01.049]

Source